InDex Pharmaceuticals Holding AB (publ) EBIT

The latest EBIT for INDEX.ST is $-56M as of March 2024. That compares with $-130M in the prior-year period — up 56.2% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside InDex Pharmaceuticals Holding AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, INDEX.ST's EBIT moved from $-130M to $-56M — a 56.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in InDex Pharmaceuticals Holding AB (publ)'s operating scale or balance-sheet position.

Against Healthcare companies, INDEX.ST currently prints $-56M for EBIT, while the sector average sits near $110B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at InDex Pharmaceuticals Holding AB (publ)'s growth, margins, and balance sheet.

A EBIT figure of $-56M for INDEX.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting INDEX.ST's EBIT ($-56M), review year-over-year change from $-130M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.